Market News

6 min read | Updated on November 18, 2026, 13:49 IST
SUMMARY
Glenmark Pharma shares advanced as much as 2.45% to hit an intraday high of ₹2,680 per unit on the NSE on Wednesday, after its subsidiary, Ichnos Glenmark Innovation, announced that it has submitted an Investigational New Drug (IND) application to the US FDA.
Stock list

On November 17, the NIFTY50 slumped as much as 0.97% to reach the day’s low of 25,141.80.
The Indian benchmark indices, SENSEX and NIFTY50, were trading in negative territory during the afternoon session on Wednesday, November 18, amid a sell-off in metal and railway PSU stocks.
Furthermore, the rupee slumped by 12 paise to a record low of 92.37 against the US dollar in early trade, as FII outflows continued for the 10th day.
The SENSEX tumbled as much as 0.91% to hit an intraday low of 81,780.47. Meanwhile, the NIFTY50 slumped as much as 0.97% to reach the day’s low of 25,141.80.
At 1:31 PM, the S&P BSE SENSEX was trading lower by 650.01 points, or 0.79%, at 81,882.18, while NSE’s NIFTY50 stood at 25,171.85, reflecting a 215.55-point, or 10.85%, decline.
The top losers in the NIFTY50 included Titan Company, HDFC Life Insurance Company, Hindalco Industries, Jio Financial Services, and Adani Enterprises.
On the contrary, the top gainers were Cipla, Tata Consumer Products, Dr. Reddy's Laboratories, Trent, and Oil and Natural Gas Corporation (ONGC).
Shares of metal and mining companies, including Hindalco Industries, Adani Enterprises, Hindustan Zinc, Steel Authority of India Ltd (SAIL), Vedanta, and more, declined on Wednesday, November 18.
The index declined amid a fall in global commodity prices, a stronger US dollar, and rising expectations that the US Federal Reserve will hike the repo rate at its upcoming FOMC (Federal Open Market Committee) meeting in December.
Shares of IIFL Finance soared as much as 7.17% to hit the day’s high of ₹682 apiece on the National Stock Exchange (NSE) on Wednesday, November 18, after a large block deal involving the company's shares was executed in the first trading session of the day.
The transaction is understood to involve FIH Mauritius Investments Limited, an investment arm of Canada's Fairfax Financial Holdings, which had put its entire stake in IIFL Finance on the block.
Ashoka Buildcon stock rallied as much as 10.1% to hit an intraday high of ₹119 per equity share on the NSE, a day after the company said it had bagged a major order.
Worth ₹1,465 crore, the civil construction firm has received a new order from the National Highways Authority of India (NHAI). The order involves the balance work for the construction of an 8-lane, access-controlled expressway from Km 154.6 to Km 190 of the Vadodara–Mumbai Expressway (Jujuwa to Gandeva section) in Gujarat under the EPC mode (Package VIII).
The order has been awarded under the Engineering, Procurement and Construction (EPC) mode and carries a defect liability period of 10 years, and it is expected to be completed in 18 months.
ACME Solar Holding shares jumped by as much as 3.08% to reach the session’s peak of ₹416.05 per unit on Wednesday, after the company announced major contract wins with a PSU power generation company.
Its subsidiary, ACME Alpha Renewable Private Limited, signed a Power Purchase Agreement (PPA) with NTPC Ltd for a 150 MW Inter-State Transmission System (ISTS) connected Hybrid power project at a tariff of ₹3.21 per unit under NTPC’s Hybrid-IV tranche.
“The tariff for this project has already been adopted by the Central Electricity Regulatory Commission (CERC),” the filing read.
Biocon shares rose 2.35% to hit an early high of ₹363.30 apiece on Wednesday’s market, after the European Commission granted marketing approval to the company to sell its breast cancer biosimilar drug, Pebrilzo, in the European Union.
The marketing approval allows any pharma company to legally sell and distribute its drugs in a specific market, in line with the health regulatory agency’s approval.
“Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach,” the company said in a press release.
The stock of SpiceJet was locked at 5% upper-circuit at ₹9.97 per equity share on the BSE on Wednesday, November 18, ahead of its fund-raiser board meeting.
Its board of directors is scheduled to meet today to consider and approve raising fresh capital by way of issuance of equity shares.
It further stated that it will raise the capital via the issuance of preference shares, debt securities and/or other permissible instruments, through preferential issue, qualified institutions placement (QIPs), or any other mode as may be considered appropriate by the board of directors.
Parag Milk Foods shares slip 2% to touch an intraday low of ₹327.01 apiece on Wednesday, November 18, despite the firm allotting 90 lakh equity shares of face value ₹10 each, following the conversion of share warrants issued on a preferential basis.
With this, the company has received the full issue consideration of ₹161 crore, including ₹121 crore received upon conversion.
The dairy and nutrition company received the balance exercise price of ₹134.32 per warrant (75% of the warrant price of ₹179.10), aggregating to ₹121 crore. Together with the 25% upfront amount received at the time of the warrant issue, the converted tranche represents a total investment of approximately ₹161 crore in the company.
The stock of Glenmark Pharmaceuticals advanced as much as 2.45% to hit an intraday high of ₹2,680 per unit on the NSE on Wednesday, after its subsidiary, Ichnos Glenmark Innovation (IGI), announced that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA).
The application was submitted for ISB 2301, an investigational multispecific immune cell activator being developed to target solid tumours, according to a regulatory filing.
The drug candidate is designed to target three tumour-associated antigens while engaging both T cells and natural killer (NK) cells to activate the immune system against cancer cells. IGI plans to initiate a Phase 1 clinical trial evaluating ISB 2301 in patients with solid tumours in 2027.
Related News
About The Author

Next Story